Unprecedented Response Rate in Advanced Bladder Cancer Unprecedented Response Rate in Advanced Bladder Cancer

The combination of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial cancer was called ' very promising ' by an expert not involved with an early phase trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news